About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Xth Eurasian Hematology-Oncology Congress
http://www.ehog.net/
Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Event
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Management of ALK+ NSCLC Through First and Subsequent Lines of Therapy: 1st vs. 2nd Generation ALK TKIs
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Perran Fulden Yumuk
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Perran Fulden Yumuk
81 views
March 18, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Lung
05:21
Xth Eurasian Hematology-Oncology Congress
Management of ALK+ NSCLC Through First and Subsequent Lines of Thera…
Feat.
P. Yumuk
17:12
Xth Eurasian Hematology-Oncology Congress
Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy…
Feat.
P. Yumuk
20:50
Xth Eurasian Hematology-Oncology Congress
Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Trea…
Feat.
M. Erman
08:26
Xth Eurasian Hematology-Oncology Congress
Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and …
Feat.
M. Erman
05:02
Xth Eurasian Hematology-Oncology Congress
Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in…
Feat.
B. Uluc
05:57
Xth Eurasian Hematology-Oncology Congress
1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced …
Feat.
B. Uluc
14:46
Xth Eurasian Hematology-Oncology Congress
Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is Treatme…
Feat.
B. Uluc